FMP
Aurinia Pharmaceuticals Inc.
AUPH
NASDAQ
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
5.05 USD
0.06 (1.19%)
About
ceo
Mr. Peter S. Greenleaf M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://www.auriniapharma.com
exchange
NASDAQ
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
CIK
0001600620
ISIN
CA05156V1022
CUSIP
05156V102
Address
4464 Markham Street
Phone
12507084272
Country
CA
Employee
300
IPO Date
Sep 3, 2014
Summary
CIK
0001600620
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
05156V102
ISIN
CA05156V1022
Country
CA
Price
5.05
Beta
1.38
Volume Avg.
2.11M
Market Cap
730.32M
Shares
-
52-Week
4.71-12.43
DCF
6.6
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-9.35
P/B
-
Website
https://www.auriniapharma.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest AUPH News
It looks like there's no news available.
